Department of Oncology of the First Affiliated Hospital, Faculty of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Department of Pathology, Anhui Medical University, Hefei, Anhui, China.
Cancer Res. 2022 Feb 1;82(3):391-405. doi: 10.1158/0008-5472.CAN-21-1155. Epub 2021 Nov 22.
Estrogen receptor alpha (ERα) plays a vital role in the development of normal breast tissue and in breast cancer. By cross-analyzing The Cancer Genome Atlas (TCGA) database, ERα-regulated long noncoding RNA 1 (ERLC1) was identified as a long noncoding RNA exhibiting a strong association with ERα signaling and high specificity of expression in breast tissue. ERLC1 was transcriptionally activated by ERα, and ERLC1 stabilized the transcript by sequestering miR-129 and tethering FXR1 to maintain a positive feedback loop that potentiated ERα signaling. ERLC1 was elevated in tamoxifen-resistant breast cancer cells, where ERLC1 depletion restored sensitivity to tamoxifen and increased the efficacy of palbociclib or fulvestrant therapy. Collectively, these data warrant further investigation of ERLC1 as a modulator of therapeutic response and potential therapeutic target in ER+ breast cancer. SIGNIFICANCE: This study identifies an estrogen-regulated lncRNA and the mechanism by which it positively regulates ERα activity, demonstrating a feedback loop that can promote resistance to antiestrogen therapies in ER+ breast cancer.
雌激素受体 alpha(ERα)在正常乳腺组织的发育和乳腺癌中起着至关重要的作用。通过对癌症基因组图谱(TCGA)数据库进行交叉分析,确定了雌激素受体调节的长非编码 RNA 1(ERLC1)是一种长非编码 RNA,它与 ERα 信号具有很强的关联,并且在乳腺组织中具有高特异性表达。ERLC1 被 ERα 转录激活,通过隔离 miR-129 和将 FXR1 固定在一起来稳定转录本,从而维持一个正反馈回路,增强 ERα 信号。ERLC1 在他莫昔芬耐药的乳腺癌细胞中升高,其中 ERLC1 耗竭恢复了对他莫昔芬的敏感性,并增加了 palbociclib 或氟维司群治疗的疗效。总之,这些数据表明 ERLC1 是治疗反应的调节剂,也是 ER+乳腺癌的潜在治疗靶点,值得进一步研究。意义:本研究鉴定了一种雌激素调节的 lncRNA 及其正向调节 ERα 活性的机制,证明了一个反馈回路,可促进 ER+乳腺癌中抗雌激素治疗的耐药性。